ITIH2

Across TCGA pan-cancer cohorts, ITIH2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ITIH2 data layer compared with 24 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ITIH2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ITIH2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where ITIH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.930	0.688	.001	38	view →
LUAD	OS	Tertile	III,IV	0.207	1.000	.001	34	view →
UCEC	DFS	Tertile	All	0.837	0.969	.011	28	view →
COAD	DFS	Median	II,III,IV	0.880	1.000	.020	24	view →
LSCC	OS	Median	All	0.922	1.000	.010	11	view →
GBM	DFS	Median	All	0.277	0.477	.009	5	view →
PDAC	OS	Median	II,III,IV	0.798	0.884	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ITIH2–CCRCC (DFS)

Open the CCRCC breakdown →